A phase 3 multicenter, randomized, placebo-controlled, double-blind study to evaluate the efficacy and safety of eneboparatide (

A phase 3 multicenter, randomized, placebo-controlled, double-blind study to evaluate the efficacy and safety of eneboparatide (AZP-3601), a parathyroid hormone receptor agonist, in patients with chronic hypoparathyroidism (CALYPSO)

Open

Protocol code: AZP-3601-CLI-002
EudraCT code: _
Research group: Diabetes and Metabolism
Service: Endocrinology
Principal investigator: Fidilio Meli, Enzamaría
Pathology: Símptomes, signes i troballes anormals clíniques i de laboratori, no classificades enlloc més
Phase: Fase III
Status: Recruiting volunteers